UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event Reported): July 31, 2017
Curis, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware | 000-30347 | 04-3505116 | ||
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification Number) | ||
4 Maguire Road, Lexington, MA 02421 | ||||
(Address of Principal Executive Offices) (Zip Code) |
(617) 503-6500
(Registrants telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
This Form 8-K and the exhibits attached hereto contain forward-looking statements of Curis, Inc. (Curis, we or the Company) that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Form 8-K and the attached exhibits are forward-looking statements. The words anticipate, believe, estimate, expect, intend, may, plan, predict, project, target, potential, will, would, could, should, continue, contemplate, or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about: the initiation, timing, progress and results of our preclinical studies and clinical trials; plans to develop and commercialize our drug candidates; the timing or likelihood of regulatory filings and approvals; our commercialization, marketing and manufacturing capabilities and strategy; the rate and degree of market acceptance and clinical utility of our products; developments and projections relating to our competitors and our industry; and the potential of CUDC-907, CA-170, CA-327, CA-4948, and any additional drug candidates that we may acquire in the future. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make due to a number of important factors. For example, we may experience adverse results, delays and/or failures in our drug development programs and may not be able to successfully advance the development of our drug candidates in the time frames we project, if at all. Our drug candidates may cause unexpected toxicities, fail to demonstrate sufficient safety and efficacy in clinical studies and/or may never achieve the requisite regulatory approvals needed for commercialization. Favorable results seen in preclinical studies and early clinical trials of our drug candidates may not be replicated in later trials. There can be no guarantee that the collaboration agreement with Aurigene will continue for its full term, that we or Aurigene will each maintain the financial and other resources necessary to continue financing our respective portion of the research, development and commercialization costs, or that we and Aurigene will successfully discover, develop or commercialize drug candidates under the collaboration. Regulatory authorities may determine to delay or restrict Genentechs and/or Roches ability to continue to develop or commercialize Erivedge in BCC. Erivedge may not demonstrate sufficient or any activity to merit its further development in disease indications other than BCC. Competing drugs may be developed that are superior to Erivedge. We face risks relating to our wholly-owned subsidiarys royalty-collateralized loan transaction, including the risk that it may not receive sufficient levels of royalty revenue from sales of Erivedge to satisfy the debt obligation or may otherwise lose its rights to royalties and royalty-related payments as a result of a foreclosure of the loan. We will require substantial additional capital to fund our business and such capital may not be available on reasonable terms, or at all. We face substantial competition and risks relating to potential adverse decisions made by the FDA and other regulatory authorities, investigational review boards, and publication review bodies. We may not obtain or maintain necessary patent protection and could become involved in expensive and time-consuming patent litigation and interference proceedings. Unstable market and economic conditions and unplanned expenses may adversely affect our financial condition and our ability to access the substantial additional capital needed to fund the growth of our business.
Important factors that may cause or contribute to such differences are discussed in the Risk Factors and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2016, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 and other periodic filings we make with the SEC.
The forward-looking statements included in this Current Report on Form 8-K and the exhibits attached hereto represent our views as of the date of this Form 8-K. We anticipate that subsequent events and developments will cause our views to change. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this Form 8-K.
Item 2.02. Results of Operations and Financial Condition.
On August 3, 2017, we announced our financial results for the three and six month periods ended June 30, 2017. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Current Report on Form 8-K (including Exhibit 99.1) attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 (the Securities Act) or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) On July 31, 2017, Dr. Mani Mohindru notified the Board of Directors of Curis, Inc., that, effective August 14, 2017, she will resign as the Senior Vice President, Chief Strategy Officer of the Company to pursue other opportunities.
Item 7.01. Regulation FD Disclosure.
From time to time, we conduct meetings with third parties in which we utilize a corporate slide presentation. A copy of our current corporate slide presentation, dated August 2017, is attached as Exhibit 99.2 to this Current Report on Form 8-K and, among other things, provides for an update on our recently-announced data related to CUDC-907. The attached presentation is incorporated herein by reference.
The information in this Form 8-K (including Exhibit 99.2) shall not be deemed filed for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) The Exhibits to this Current Report on Form 8-K are listed in the Exhibit Index attached hereto.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Curis, Inc. | ||||||
Date: August 3, 2017 | By: | /S/ JAMES E. DENTZER | ||||
James E. Dentzer | ||||||
Chief Financial Officer and Chief Administrative Officer |
EXHIBIT INDEX
Exhibit Number |
Description | |
99.1 | Press Release dated August 3, 2017 | |
99.2 | Slide Presentation dated August 2017 |
Exhibit 99.1
Curis Reports Second Quarter 2017 Financial Results
Management to host conference call today at 8:30 a.m. EDT
LEXINGTON, Mass., August 3, 2017 (GLOBE NEWSWIRE) Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, reported today its financial results for the second quarter ended June 30, 2017.
Curis also reported today data from the interim analysis of the Phase 2 trial of CUDC-907 in patients with MYC-altered DLBCL. Of the 36 evaluable patients with MYC-altered DLBCL in the interim analysis, 7 patients experienced confirmed durable objective responses (19.4% ORR), including 3 with complete responses. In addition, and consistent with the original hypothesis, all 7 responders in the Phase 2 study had MYC-altered disease, while no objective responses were observed in 12 patients with MYC-negative disease status.
The ability of CUDC-907 treatment to result in durable complete responses, and the continued correlation of this benefit selectively in patients with MYC-altered disease, is encouraging for the continued development of CUDC-907, said Ali Fattaey, President and CEO. While we believe the results from this Phase 2 trial are insufficient to serve as the basis of a request for accelerated approval of CUDC-907, we are evaluating alternative designs for a separate registration-enabling trial to demonstrate CUDC-907s benefit for patients with MYC-altered DLBCL.
The reported response rate is impressive, especially in this population of patients with relapsed/refractory MYC-altered lymphomas who rarely respond to salvage therapies, said Dr. Daniel J. Landsburg, Assistant Professor of Clinical Medicine at the Abramson Cancer Center at the Hospital of the University of Pennsylvania. I believe this agent warrants continued investigation.
Second Quarter 2017 Financial Results
Curis reported a net loss of $14.1 million, or $0.10 per share, on both a basic and diluted basis for the second quarter of 2017, as compared to a net loss of $11.3 million, or $0.09 per share, on both a basic and diluted basis for the same period in 2016. Curis reported a net loss of $29.8 million, or $0.21 per share, on both a basic and diluted basis for the six months ended June 30, 2017, as compared to a net loss of $20.7 million, or $0.16 per share on both a basic and diluted basis for the same period in 2016.
Revenues for the second quarter of 2017 were $2.1 million, as compared to $1.7 million for the same period in 2016. Revenues for the six months ended June 30, 2017 were $4.2 million, as compared to $3.4 million for the same period in 2016. Revenues for both periods comprise primarily royalty revenues recorded on Genentech and Roches net sales of Erivedge®.
Operating expenses were $15.2 million for the second quarter of 2017, as compared to $12.4 million for the same period in 2016. Operating expenses for the six months ended June 30, 2017 were $32.4 million, as compared to $22.9 million for the same period in 2016, and comprised the following:
Costs of Royalty Revenues. Costs of royalty revenues, primarily amounts due to third-party university patent licensors in connection with Genentech and Roches Erivedge net sales, were $0.1 million for both the second quarter of 2017 and 2016. Cost of royalty revenues for the six months ended June 30, 2017 and 2016 were $0.2 million for both periods.
Research and Development Expenses. Research and development expenses were $11.3 million for the second quarter of 2017, as compared to $8.8 million for the same period in 2016. The increase was primarily due to increased direct spending related to clinical activities of CUDC-907 and CA-170 and increased employee-related expenses primarily due to additional headcount to support the multiple programs. Research and development expenses were $24.8 million for the six months ended June 30, 2017 as compared to $15.7 million for the same period in 2016.
General and Administrative Expenses. General and administrative expenses were $3.8 million for the second quarter of 2017 as compared to $3.4 million for the same period in 2016. The increase in general and administrative expenses was driven primarily by higher personnel costs and stock-based compensation expense due to increased headcount. General and administrative expenses were $7.4 million for the six months ended June 30, 2017, as compared to $7.1 million for the same period in prior 2016.
Other expense, net was $1.0 million for the second quarter of 2017, as compared to $0.6 million for the same period in 2016. Other expense, net primarily consisted of interest expense related to Curis Royaltys (a wholly owned subsidiary of Curis) debt obligations. Other expense, net was $1.7 million and $1.2 million for the six months ended June 30, 2017 and 2016, respectively.
As of June 30, 2017, Curiss cash, cash equivalents, marketable securities and investments totaled $51.0 million and there were approximately 143.9 million shares of common stock outstanding. On a fully-diluted basis, which includes 18.6 million options, there were 162.5 million shares outstanding.
Recent Operational Highlights
Precision oncology (CUDC-907: HDAC / PI3K inhibitor program):
The following summarizes the CUDC-907 Phase 1 trial results and Phase 2 interim analysis:
CUDC-907 Phase 1 and Phase 2 (Interim) Trial Results
Monotherapy in relapsed/refractory DLBCL
Immuno-oncology (CA-170: PD-L1 / VISTA antagonist program; Aurigene collaboration):
| In May 2017, Curis presented the CA-170 Phase 1 trials-in-progress poster at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting. |
Upcoming Activities
Curis expects that it will make presentations at the following conferences through September 2017:
| CA-170 poster presentation at the European Society for Medical Oncology (ESMO) Conference (Sept. 8-12, 2017) in Madrid. |
Conference Call Information
Curis management will host a conference call today, August 3, 2017, at 8:30 a.m. EDT to discuss these financial results and provide a corporate update.
To access the live conference call please dial (877) 868-1829 from the United States or (253) 237-1135 from other locations shortly before 8:30 a.m. EDT. The conference ID number is 61970970. The conference call can also be accessed on the Curis website at www.curis.com in the Investors section.
About Curis
Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907 which is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit
the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in myelofibrosis. For more information, visit Curiss website at www.curis.com.
Cautionary Note Regarding Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding any expectations of revenue, expenses, earnings or losses from operations, or other financial results, statements with respect to the plans, strategies and objectives of management for future operations, the potential for the Companys proprietary drug candidates, including CUDC-907, the potential advantages and benefits of small molecule checkpoint antagonists, the Companys plans and expectations for the collaboration with Aurigene, including its plans to discover and develop multiple first-in-class oral, small molecule checkpoint antagonists for the treatment of patients with cancer, and the Companys plans to advance its development programs, including the timing of IND filings and the Companys plans for CUDC-907. Forward-looking statements may contain the words believes, expects, anticipates, plans, seeks, estimates, assumes, will, may, could or similar expressions. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties, assumptions and other important factors that may cause actual results to be materially different from those indicated by such forward-looking statements. For example, Curis may experience adverse results, delays and/or failures in its drug development programs and may not be able to successfully advance the development of its drug candidates in the time frames it projects, if at all. Curiss drug candidates may cause unexpected toxicities, fail to demonstrate sufficient safety and efficacy in clinical studies and/or may never achieve the requisite regulatory approvals needed for commercialization. Favorable results seen in preclinical studies and early clinical trials of Curiss drug candidates may not be replicated in later trials. There can be no guarantee that the collaboration agreement with Aurigene will continue for its full term, that Curis or Aurigene will each maintain the financial and other resources necessary to continue financing its portion of the research, development and commercialization costs, or that the parties will successfully discover, develop or commercialize drug candidates under the collaboration. Regulatory authorities may determine to delay or restrict Genentechs and/or Roches ability to continue to develop or commercialize Erivedge in BCC. Erivedge may not demonstrate sufficient or any activity to merit its further development in disease indications other than BCC. Competing drugs may be developed that are superior to Erivedge. Curis faces risks relating to its wholly-owned subsidiarys royalty-collateralized loan transaction, including the risk that it may not receive sufficient levels of royalty revenue from sales of Erivedge to satisfy the debt obligation or may otherwise lose its rights to royalties and royalty-related payments as a result of a foreclosure of the loan. Curis will require substantial additional capital to fund its business and such capital may not be available on reasonable terms, or at all. Curis faces substantial competition. Curis also faces risks relating to potential adverse decisions made by the FDA and other regulatory authorities, investigational review boards, and publication review bodies. Curis may not obtain or maintain necessary patent protection and could become involved in expensive and time consuming patent litigation and interference proceedings. Unstable market and economic conditions and unplanned expenses may adversely affect Curiss financial conditions and its ability to access the substantial additional capital needed to fund the growth of its business. Important factors that may cause or contribute to such differences include the factors set forth
under the caption Risk Factors in our most recent Form 10-K and Form 10-Q and the factors that are discussed in other filings that we periodically make with the Securities and Exchange Commission (SEC). In addition, any forward-looking statements represent the views of Curis only as of today and should not be relied upon as representing Curiss views as of any subsequent date. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by law.
CURIS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
(In thousands, except share and per share data)
Three months ended | Six months ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2017 | 2016 | 2017 | 2016 | |||||||||||||
Revenues: |
||||||||||||||||
Royalties |
$ | 2,102 | $ | 1,842 | $ | 4,294 | $ | 3,586 | ||||||||
Research and development, net |
(41 | ) | (162 | ) | (102 | ) | (180 | ) | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Total revenues: |
2,061 | 1,680 | 4,192 | 3,406 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Operating expenses: |
||||||||||||||||
Costs of royalty revenues |
96 | 95 | 207 | 184 | ||||||||||||
Research and development |
11,255 | 8,822 | 24,795 | 15,650 | ||||||||||||
General and administrative |
3,819 | 3,443 | 7,351 | 7,059 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total operating expenses |
15,170 | 12,360 | 32,353 | 22,893 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net loss from operations |
(13,109 | ) | (10,680 | ) | (28,161 | ) | (19,487 | ) | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Other (expense) income |
| | (104 | ) | | |||||||||||
Interest income |
138 | 119 | 208 | 224 | ||||||||||||
Interest expense |
(1,119 | ) | (729 | ) | (1,775 | ) | (1,468 | ) | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Other expense, net |
(981 | ) | (610 | ) | (1,671 | ) | (1,244 | ) | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Net loss |
(14,090 | ) | (11,290 | ) | (29,832 | ) | (20,731 | ) | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Basic and diluted net loss per common share |
$ | (0.10 | ) | $ | (0.09 | ) | $ | (0.21 | ) | $ | (0.16 | ) | ||||
|
|
|
|
|
|
|
|
|||||||||
Basic and diluted weighted average common shares outstanding |
143,786,705 | 129,270,639 | 142,904,144 | 129,142,989 | ||||||||||||
|
|
|
|
|
|
|
|
CURIS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(In thousands)
June 30, 2017 |
December 31, 2016 |
|||||||
ASSETS |
||||||||
Cash, cash equivalents and investments |
$ | 51,042 | $ | 44,485 | ||||
Investments restricted |
153 | 153 | ||||||
Accounts receivable |
2,231 | 2,459 | ||||||
Property and equipment, net |
426 | 413 | ||||||
Goodwill |
8,982 | 8,982 | ||||||
Prepaid expenses and other assets |
961 | 1,260 | ||||||
|
|
|
|
|||||
Total assets |
$ | 63,795 | $ | 57,752 | ||||
|
|
|
|
|||||
LIABILITIES AND STOCKHOLDERS EQUITY |
||||||||
Accounts payable, accrued expenses and other liabilities |
$ | 10,682 | $ | 8,626 | ||||
Debt obligations, net |
43,885 | 19,860 | ||||||
|
|
|
|
|||||
Total liabilities |
54,567 | 28,486 | ||||||
Total stockholders equity |
9,228 | 29,266 | ||||||
|
|
|
|
|||||
Total liabilities and stockholders equity |
$ | 63,795 | $ | 57,752 | ||||
|
|
|
|
For More Information:
James E. Dentzer
Chief Financial Officer & Chief Administrative Officer
Curis, Inc.
617-503-6500
jdentzer@curis.com
Media Contact
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com
Corporate Presentation August 2017 Exhibit 99.2
This presentation contains certain forward-looking statements about Curis, Inc. (“we,” “us,” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “expect(s),” “feel(s),” “believe(s),” “will,” “may,” “anticipate(s)” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are statements that are not historical facts, reflect management’s expectations as of the date of this presentation, and involve risks and uncertainties. Forward-looking statements herein include, but are not limited to, statements with respect to the timing and results of future clinical and pre-clinical milestones; the timing of future preclinical studies and clinical trials and results of these studies and trials; the clinical and therapeutic potential of our drug candidates; and management’s ability to successfully achieve its goals. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of important factors including, without limitation, risks relating to: whether any of our drug candidates will advance further in the clinical development process and whether and when, if at all, they will receive approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies; whether historical preclinical results will be predictive of future clinical trial results; whether historical clinical trial results will be predictive of future trial results; whether any of our drug candidate discovery and development efforts will be successful; whether any of our drug candidates will be successfully marketed if approved; our ability to achieve the benefits contemplated by our collaboration agreements; management’s ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; general economic conditions; competition; and the other risk factors contained in our periodic and interim reports filed with the Securities and Exchange Commission which are available on the SEC website at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events, except as required by law. Forward Looking Statements
Mission: Innovative Medicines to Treat Cancer Effectively Precision Oncology Oncology-Focused Biotech Pipeline of differentiated small molecule cancer drug candidates Developing and intend to commercialize oncology drugs Partnerships: Aurigene, Genentech/Roche Immuno-oncology
Program Indication Stage of Development Preclinical Phase 1 Phase 2 Phase 3 Marketed CUDC-907 HDAC / PI3K MYC-Altered DLBCL MYC-Driven Solid Tumors CA-170 * PD-L1 / VISTA Solid Tumors & Lymphomas CA-327 * PD-L1 / TIM3 Cancers CA-4948 * IRAK4 Hematologic malignancies Erivedge® ** Smoothened Advanced Basal Cell Carcinoma Immuno-oncology and Precision Oncology Orally available small molecules * Licensed from Aurigene **Developed and marketed by Genentech (Curis receives royalty income)
CUDC-907 has the potential to become a treatment for MYC-altered cancers CUDC-907 Phase 2 drug candidate to treat MYC-driven cancers Program Indication Stage of Development Preclinical Phase 1 Phase 2 Phase 3 Marketed CUDC-907 HDAC / PI3K MYC-Altered DLBCL MYC-Driven Solid Tumors
HDACi PI3Ki CUDC-907 Oral, small molecule inhibitor of HDAC & PI3K enzymes Down-regulates MYC mRNA and protein levels Phase 1 heme study completed (88 patients) – relapsed/ refractory (R/R) lymphoma or multiple myeloma Favorable safety and tolerability observed Objective responses (CRs and PRs) in patients with R/R DLBCL, including in MYC-altered tumors Phase 2 trial in MYC-altered R/R DLBCL ongoing Orphan designation in DLBCL Enzyme HDAC PI3K Isotype 1 2 3 6 10 Alpha Delta Beta Gamma IC50 (nM) 1.7 5 1.8 27 2.8 19 39 54 311 CUDC-907 Control 1000 100 10 1 0.1 Ac-H3 pAKT MYC BCL2 (nM)
CUDC-907 Phase 1 and Phase 2 Trial Parameters Study Population Relapsed or refractory lymphoma or multiple myeloma after ≥2 prior regimens Total of 88 patients enrolled Objectives Primary: MTD, recommended Phase 2 dose (RP2D) Secondary: Safety and tolerability, pharmacokinetics, biomarkers, anti-cancer activity Treatment: Oral, once daily dosing – different administration schedules QD: 30mg, 60mg BIW or TIW: escalation from 60mg – 150mg 5/2 (5 days on, 2 days off): 60mg (selected as recommended Phase 2 dose, RP2D) Study Population Relapsed or refractory DLBCL after ≥ 2 but no more than 4 prior regimens 100 subjects with centrally-confirmed MYC-altered disease for full study Up to 50 total and 25 evaluable subjects with MYC-altered disease for interim analysis Objectives Primary: Efficacy as measured by ORR Secondary: PFS, OS, DCR, DoR Treatment Oral 60mg once daily dosing on 5/2 schedule Participating centers 21 centers enrolled subjects in US and Europe Phase 1 (Completed) Phase 2 ongoing
CUDC-907 Phase 1 and Phase 2 Interim Trial Results Monotherapy in relapsed/refractory DLBCL Favorable safety and tolerability observed to date Durable responses, including a number of CRs observed Responses predominately observed in patients with MYC-altered disease status Phase 1 Trial (Interim) Phase 2 Trial (ITT) # Patients 25 44 (Evaluable) # Patients 19 36 CR 3 3 PR 6 4 SD 4 4 PD 6 25 Not Evaluable 6 8 (ITT) ORR 36.0% 15.9% (Evaluable) ORR 47.4% 19.4% Median DoRx 15.5 mo. NR* *Median Duration on Treatment in Phase 2 not yet reached # of Patients # of Responses Phase 1 Trial MYC+ 8 4 50.0% MYC- 7 2 28.6% Unknown 10 3 30.0% Phase 2 Trial MYC+ 44 7 15.9% MYC- 12 0 0.0% Unknown 12 0 0.0%
CUDC-907 Phase 2 Trial Status Monotherapy in MYC-altered relapsed/refractory DLBCL Open label study to evaluate the efficacy and safety of CUDC-907 monotherapy in patients with relapsed/refractory (R/R) DLBCL – after 2 prior treatments Study Status Interim analysis conducted following enrollment of 68 patients No new safety findings Durable CRs and PRs observed selectively in patients with MYC-altered DLBCL ORR of 19.4% in evaluable patients is below internally-set threshold of 30% Evaluating alternative designs for a separate registration-enabling trial to better capture and demonstrate CUDC-907 benefit in patients with MYC-altered DLBCL
CA-170 is a first-in-class oral small molecule immune checkpoint inhibitor In Phase 1 clinical development CA-170 Oral, small molecule checkpoint inhibitor – PDL1 and VISTA Program Indication Stage of Development Preclinical Phase 1 Phase 2 Phase 3 Marketed CA-170 PD-L1 / VISTA Solid Tumors & Lymphomas
Small Molecule Checkpoint Inhibitors Oral, small molecules designed to bind inhibitory checkpoints Common folding structure in the extracellular domain PD-L1Expressed on immune and tumor cells VISTAExpressed on myeloid cells, including MDSCs TIM3Co-expressed with PD-1 on highly exhausted CD8+ T cells Multi-year, exclusive collaboration with Aurigene Curis option to royalty-bearing license for multiple programs PD-1 PD-L1 Extracellular Domain Interaction
CA-170 Concentration (log nM) Activation (%) CA-170 is a Checkpoint inhibitor Ex-vivo and in vivo T cell activation and anti-tumor activity Increase in Activated CD8+ T cells In vivo Activation of PDL1 or VISTA-inhibited T cells Activation (%) CA-170 Concentration (log nM) Anti-Tumor Activity In vivo (B16/F1 melanoma) IFN-g production
CA-170 Phase 1 Trial Dose escalation stage Patient Population Patients with advanced solid tumors or lymphoma Study sites in US, EU, and Asia Objectives Safety/Tolerability, PK, PD, Recommended Phase 2 Dose (RP2D), anti-cancer activity Treatment Oral, once daily, dosing in continuous 21-day cycles Dose escalation as needed until RP2D is identified “back-filling” of additional patients at Dose Level 4 & higher is allowed Dose Level 1 50mg QD n=1 Dose Level 2 100mg QD n=1 Dose Level 3 200mg QD n=1 Dose Level 4 400mg QD n=1 Dose Level 5 600mg QD n=3 Dose Level 6 800mg QD n=3
CA-170 Oral Exposure in Patients 50mg – 800mg dose – continuous once daily dosing PK profile in patients was similar to PK observed in non-clinical models Cmax and AUC at 50mg starting dose in patients was similar to 10mg/kg dose in mouse (active dose) Dose proportional increase in exposure with increasing doses in patients Near-linear doubling in Cmax and AUC with dose doubling: 50mg – 800mg daily dose Human PK Profile 50 100 200 400 600 800 50 100 200 400 600 800 Cycle 1, Day 1 Cycle 1, Day 15 Cmax (ng/ml) Cycle 1, Day 1 Cycle 1, Day 15 AUC (ng*hr/ml)
CA-170 is a Checkpoint Inhibitor in Patients Increase in T cells in Tumor Increase in CD8+ T cells in patient tumor biopsies after CA-170 treatment Assessed after first cycle of CA-170 treatment at 600mg dose (21 days) Patient with colorectal cancer, 5 prior treatments; immunotherapy treatment-naïve Flow Cytometry of blood sample (Day 1) IHC staining of tumor biopsies (After Cycle 1) Pre-dose Post Cycle 1 Automated Quantitation NanoString Profile
CA-170 Phase 1b Trial Dose expansion design and plans Melanoma NSCLC RCC HL TNBC HNSCC CRC Bladder Gastric + Etc CA-170 Treatment Clinical Parameters Tumor and Immune Profile Parameters Tumor shrinkage Duration on treatment AE / irAE profile Tumor infiltrate profile Gene expression profile Expression of targets Real-time analysis & correlation PD1/L1-approved indications PD1/L1-non-approved indications Curis Confidential Biomarker or signature-defined patient selection NSCLC TNBC HNSCC CRC Gastric Ovarian Prostate Esophageal
CA-327 is an oral, small molecule immune checkpoint inhibitor IND filing expected in Q1 2018 CA-327 Oral, small molecule checkpoint inhibitor – PDL1 and TIM3 Program Indication Stage of Development Preclinical Phase 1 Phase 2 Phase 3 Marketed CA-327 PD-L1 / TIM3 Cancers
CA-327 Is a Checkpoint Inhibitor Selectively targets PDL1 and TIM3 CA-327 Vehicle Blood CD8+/CD69+ T cells Vehicle Control Anti-PD1 Antibody 1mg/kg CA-327 Tumor CD8+/CD69+ T cells Vehicle Control Anti-PD1 Antibody 1mg/kg CA-327 Tumor Model Treatment % TGI at Dose (mg/kg) 1 3 10 B16F10 melanoma CA-327 45 41 52 Anti-PD1 5 Anti-TIM3 18 MC38 colon carcinoma CA-327 24 33 40 Anti-PD1 34 CA-170 35 CA-327+ CA-170 65 Increase in Activated CD8+ T cells In vivo Anti-Tumor Activity In vivo (B16/F1 melanoma) Summary in vivo dose dependent Tumor Growth Inhibition
CA-4948 is an oral, small molecule inhibitor of IRAK4 IND filing expected in 3Q 2017 (Phase 1 trial in Non-Hodgkin’s Lymphoma) CA-4948 Oral, small molecule inhibitor of IRAK4 Program Indication Stage of Development Preclinical Phase 1 Phase 2 Phase 3 Marketed CA-4948 IRAK4 Heme malignancies
IRAK4 kinase is a critical component of toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways – implicated in certain cancers IRAK4 kinase, through IRAK1 is critical for NF-kB activation for cytokine secretion & cell survival Recruitment of IRAK4 to TLR/ IL-1R mediated by myD88 adaptor protein Activating MYD88 mutations are found in certain lymphomas; making IRAK4 an attractive target CA-4948 and IRAK4 Validated target in MYD88-mutated non-Hodgkin’s lymphomas Activation
Prevalence of Oncogenic MYD88 Mutations Non-Hodgkin lymphomas Indication MYD88-L265P Diffuse Large B-cell Lymphoma (ABC-DLBCL) 15-29% Immune-privileged DLBCL (IP-DLBCL) 50-80% Waldenstrom’s Macroglobulinemia (WM) 95-97% Lymphoplasmacytic Lymphoma (LPL) 79% Splenic Marginal Zone Lymphoma (SMZL) 6-10% Mucosa-Associated Lymphoid Tissue (MALT) 9% Chronic Lymphocytic Leukemia (CLL) 2.9%
CA-4948 Exhibited Significant In vivo Activity MYD88-mutant DLBCL tumor models CA-4948 is a potent and selective IRAK4 inhibitor In vivo anti-tumor activity in multiple MYD88-mutant (L265P) vs. MYD88-wt DLBCL tumor models
Program Indication Stage of Development Preclinical Phase 1 Phase 2 Phase 3 Marketed CUDC-907 HDAC / PI3K MYC-Altered DLBCL MYC-Driven Solid Tumors CA-170 * PD-L1 / VISTA Solid Tumors & Lymphomas CA-327 * PD-L1 / TIM3 Cancers CA-4948 * IRAK4 Hematologic malignancies Erivedge® ** Smoothened Advanced Basal Cell Carcinoma Immuno-oncology and Precision Oncology Orally available small molecules * Licensed from Aurigene **Developed and marketed by Genentech (Curis receives royalty income)
CA-170 Phase 1 initial data, Clinical profilen Q3 2017ESMO n Q4 2017SITC CA-4948 IND filing n Q3 2017 CA-327 IND filing n Q1 2018 2017 Projected Milestones
$51.0MCash & Marketable Securities 143.9MShares Outstanding - Basic 162.5MShares Outstanding - Fully Diluted* *Diluted Shares = 143.9M basic shares + 18.6M options Summary of Financials As of June 30, 2017
END
Q\>_VC/C'^
MT?XFOO&GQI\;:IXKG#W%S8: ))+3PAX:MN9!I_AGPQ%(=-T^WMU&Q+EXY]3N
MB//O;Z>9V<_K+X:_X(KZEX@_9GT_XJR_%XV?Q6U?P%#\0=-\%IH%A+X$CAO=
M(77K#PQ>ZPTO]KM>S6$D4%SKD*K:6VHR/Y=A/9QB1_PU90RE6 96!5@1D$$8
M((]".#7VSI7_ 41_:YT7X'?\,]Z?\2XHO ::"_A.VU%]#LY/'-CX4D@-H?#
MMEXN>0W4-C'8DZ=;W+VTNJVVGXM+?4(XXX]OD9_EG$4<+E&"X+Q>7Y)2PN+I
M_6J4J%.$/J<.51C1A'#UH*,&G*I3C3A4K.2_?+WD_5R+,GG>WEOMK^%/AS_D6O#G'_ #+VC_A_H-O_ /JK
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MWJ>D!#YPN[.32M"8O /-4F)%(\W#?A7"H$,*QDLOEQ;6W%RR[5P=W)
M&M+&XO%\0TJ6)ITJL,+3E@
M*N+Q>(6"PBJ2_GHG^%WQ*M;SQE8W/P\\ (O@_\./@E\.? ^M_%76/A[JU]X3\5
M_S>-]$M?$?B#Q/XR\3:)+8ZY?6UI;S:?_ &?I8OUL[>6X>W=);73-(@LL
M "Q$*N)6#PE? 4,*UB,1!U*-2DXUH*3K
M8>D_PG"O'(\;JR21L\ SIQKU)5L2IJET97')*
M?!'$F._LRK4SB-7* C
MD\\[S:>,QE:G@J6&6+QN%P=#!5*5"55U 8X[GRKA]N6#6!Y:?+6SNRG]=S#
M!.\MTJ:J+1\SC=7^AAA(8G),O<\PP&"Y ?]#7*O_+S_P"9_7^GI_%Y
MGV/YO_A1GV/YO_A7]H?_ PI^P;_ -&U_#?_ ,$4_P#\F4?\,*?L&_\ 1M?P
MW_\ !%/_ /)E'_$PW#>G_"%GG3K@/[O_ $_]?Z6A_P 08SS_ *&N5?\ EY_\
MS^O]/3^+S/L?S?\ PHS['\W_ ,*_M#_X84_8-_Z-K^&__@BG_P#DRC_AA3]@
MW_HVOX;_ /@BG_\ DRC_ (F&X;T_X0L\Z=9]C^;_X49]C^;_X5_:'_ ,,*?L&_]&U_#?\ \$4__P F4?\
M#"G[!O\ T;7\-_\ P13_ /R91_Q,-PWI_P (6>=.N _N_P#3_P!?Z6A_Q!C/
M/^AKE7_EY_\ ,_K_ $]/XO,^Q_-_\*,^Q_-_\*_M#_X84_8-_P"C:_AO_P""
M*?\ ^3*/^&%/V#?^C:_AO_X(I_\ Y,H_XF&X;T_X0L\Z==.N _N_]/\
MU_I:'_$&,\_Z&N5?^7G_ ,S^O]/3^+S/L?S?_"C/L?S?_"O[0_\ AA3]@W_H
MVOX;_P#@BG_^3*/^&%/V#?\ HVOX;_\ @BG_ /DRC_B8;AO3_A"SSIUP']W_
M *?^O]+0_P"(,9Y_T-\"_ 7XH>+_A)\,=;_:[T;PYX*\&?#'6+SPAHWB")
M?B'8:%XE^(GCRUT22"/Q_P"*?&>EZ9J.KZWJ'B[^UX8=&FMO#]E!;:+IT%J/
M#RWC+.*]&;R; 8.5.OD^;\98S&YUF>85:&!P$\YQU#*Z-*G3C4Q'+CL!@:F)
MIX:E[+#X2,:DH3C",:57W,VX$R.C6H+.,PQ?-A\\R3@? 8'(LHP%#%9ACZ.2
MX'$YO4J2E6H4?:Y?C\RP^'J8FLL16QBE%RIQ>E#\POV7?V9?'G[3'Q_\!?!#
M0M!\6VG]N^.O#OACX@:YI_AC5=4E^&.@:CK\>D:]XH\46QM%@\/0Z'$E\/\
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MU*[^P:9 R6MF)I%AB0,17K9WG_ !#Q.\3.P>2X;@_(<57R_VN(G7I9GQ
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M1=+'<^89G_3S_@FS+-\)_P!E?_@I_P#M0^8MI>>&OV
O'#T)WJT
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M[3/Q0_8_^%?[&G[%7P-\6ZC\+=?^'O[*/@76_C!X\\&R#0_B)/>?$""/59_
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M4L8FL)*E3J)5*D85J?H9-P%E^#SRI@9XGZUE6-XAX%RV4
&PR5.-2&$J2PV'J5<+.
M=*#7-0XZSJAE=/+81R]U*&7XW*,+F\\)3J9U@\IS*I6K8[+L-CJCER4*\\5B
M_P!XZ3Q5.&*Q%.EB(PJRB_V3\6_M5?\ !/\ _:0_9T_91\-_M+^'OVI/#/Q9
M_9'^$O\ PI^P\&? ]/A[%\/OBUX>L)[*XTZ\?Q=XKFNK_P WFJO80MKFH6^
MA7M_8O<7GV"VU00:;+%B?M*_\% ?@C^T';_\$Z? UA\*M:^&'P5_9,>WNOB5
M\-?#-A9W.FHESXU\*:C?:%\.9-1\07-UXI6W\%>>F?Q/XON=#U3Q/K^IZC
MK>I6MK)?SA?R&Y]/T'_Q5)@^@_(?_%5P4. ,CH8FAB/;9M5C@L3F>*R[#5
!?&6LZGX
5.%&@Z='"PA:%"G32C'WI,^BQW%F _^8/R_
MZGOE^'FP_LNA_P!#W(__ ;F?E_U*O/\/6WR?@?W?_0?\:,#^[_Z#_C7UA_P
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MLR_LNA_T/H_MO$?]$[GO_F#\O\ J>^7X>;#^RZ'_0]R/_P;F?E_U*O/\/6WR?@?W?\
MT'_&C _N_P#H/^-?6'_"9_L.?]$ _:2_\2+\&?\ SGJ/^$S_ &'/^B ?M)?^
M)%^#/_G/4?VWB/\ HG<]_P#,'Y?]3WR_#S8?V70_Z'N1_P#@W,_+_J5>?X>M
MO#/AU\5?BC\'M>?Q5\)?B#XK^&WB:2S;3YM;\)W\-G?X>MOD_ _N_\ H/\ C1@?W?\
MT'_&OK#_ (3/]AS_ *(!^TE_XD7X,_\ G/4?\)G^PY_T0#]I+_Q(OP9_\YZC
M^V\1_P!$[GO_ )@_+_J>^7X>;#^RZ'_0]R/_ ,&YGY?]2KS_ ];?)^!_=_]
M!_QHP/[O_H/^-?6(\9_L.]O@!^TC^/[17@O^OP>KU?QYX?\ V(_ _@#X&^.I
M/@S^T7J2?&GPCXN\50Z;%\?O"5M+X?3PKX^UGP,]G<7$GPGFCU%[Y])&I1S0
M0V:P1W"VK12R1&=^>IQ+*C6PU"IP_GT:F+JNCA_?X>MOD_ _N_\ H/\ C1@?W?\ T'_&OK#_ (3/]AS_ *(!^TE_XD7X
M,_\ G/4?\)G^PY_T0#]I+_Q(OP9_\YZC^V\1_P!$[GO_ )@_+_J>^7X>;#^R
MZ'_0]R/_ ,&YGY?]2KS_ ];?)^!_=_]!_QHP/[O_H/^-?6'_"9_L.?]$ _:
M2_\ $B_!G_SGJ/\ A,_V'/\ H@'[27_B1?@S_P"<]1_;>(_Z)W/?_,'Y?]3W
MR_#S8?V70_Z'N1_^#H_X3/]AS_H@'[27_B1?@S_ .<]
M1_;>(_Z)W/?_ #!^7_4]\OP\V']ET/\ H>Y'_P"#H_MO$?]$[GO_F#\O\ J>^7X>;#^RZ'_0]R/_P;F?E_U*O/\/6W
MS;X3 _X2[P=\O_,X>%/[O_0PZ;[U_H)+_%_O&OXF/#?C']B1_$WAA+3X!_M&
MQ7;>)_#BVDMQ^T/X.EMX;MM;L%MIKB%/A!&\T$4YCDFA22-Y8U:-9(RP)_@W\(/B\_Q'\.
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MHT/[)PV9X>